NICE final guidance backs Pfizer’s Lorviqua
The drug meets NICE’s criteria to be considered a life-extending treatment
Read More
Tag: lorlatinib
Pfizer’s new lung cancer drug bags US clearance
Pfizer’s new lung cancer treatment Lorbrena has bagged US approval for previously treated patients with a specific gene mutation and metastatic disease.
Read More
Pfizer’s lorlatinib clears first hurdle to UK early access scheme
Pfizer’s lorlatinib has been designated a Promising Innovative Medicine for the treatment of some patients with ALK-positive advanced non-small cell lung cancer.
Read More
Pfizer’s lorlatinib impresses in Phase II lung cancer trial
Pfizer has presented Phase II data showing that its next-generation tyrosine kinase inhibitor lorlatinib exhibited “clinically meaningful activity” against lung tumours and brain metastases.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
